2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 336

The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
Abstract Number: 1022

The Risk of Symptomatic Knee Osteoarthritis after Arthroscopic Meniscus Repair Vs Partial Meniscectomy Vs the General Population
Abstract Number: 818

The Role of Endothelin 1 in Activation of Vascular Smooth Muscle Cells in Systemic Sclerosis; Increased Cell Proliferation and Resistance to Apoptosis Mediated By Endotehlin B Receptors
Abstract Number: 1749

The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis
Abstract Number: 1377

The Role of Muscle MRI in Detecting a Flare-up of Juvenile Dermatomyositis
Abstract Number: 1574

The Role of Shelterin Deficiency in the Senescence in T Cells of Rheumatoid Arthritis
Abstract Number: 1830

The Role of Tripartite Motif-Containing 21 in Interferon Signature of Systemic Lupus Erythematosus
Abstract Number: 1361

The Role of Von Willebrand Factor Antigen As a Disease Biomarker in the Clinical Assessment of Children with Juvenile Dermatomyositis
Abstract Number: 204

The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Abstract Number: 200

The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand
Abstract Number: 970

The Serotonin Receptor 2 Inhibitor Terguride Has Beneficial Effects on Skin Fibrosis: Results from a Phase 2 Proof of Concept Study
Abstract Number: 2587

The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Abstract Number: 527

The Summed Bilateral Elbow Extension Angle in Rheumatoid Arthritis Correlates with the DAS28-CRP(4) and May be an Independent Marker of Bad Prognosis
Abstract Number: 2906

The Survival and Prognostic Factors of Patients with Systemic Sclerosis Turkish Experience
Abstract Number: 2015

The Systemic Sclerosis Disease State Is Associated with Specific Alterations in Gastrointestinal Microbiota in Two Independent Cohorts

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].